Desvenlafaxine Tablet, Extended Release
Product Images NDC 71335-2130

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Desvenlafaxine (NDC 71335-2130). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Desvenlafaxine Figure1)

A forest plot chart illustrating the geometric mean ratio (90% confidence interval) of pharmacokinetic parameters Cmax and AUC for Desvenlafaxine extended release tablets. The chart compares these parameters across groups with varying renal impairment (mild, moderate, severe, ESRD), hepatic impairment (mild, moderate, severe), and population demographics by gender and age (65 to 75 years, and over 75 years), showing change relative to reference values on the x-axis from 0.5 to 3.5.*

FDA Label Image

Figure 2 (Desvenlafaxine Figure2)

A chart showing the geometric mean ratio (90% CI) of pharmacokinetic changes in Desvenlafaxine when coadministered with CYP3A4 inhibitors, specifically ketoconazole. The chart presents Cmax and AUC values relative to a reference, with Cmax around 1.08 and AUC around 1.43, indicating changes in drug exposure.*

FDA Label Image

Figure 3 (Desvenlafaxine Figure3)

A geometric mean ratio chart with 90% confidence intervals depicting the pharmacokinetic interactions of Desvenlafaxine at various doses (50 mg, 100 mg, and 400 mg) with interacting drugs including Desipramine, Midazolam, Tamoxifen, and Aripiprazole. The chart shows changes relative to reference values in Cmax and AUC parameters across CYP2D6, CYP3A4, and combined CYP2D6 & CYP3A4 substrates.*

FDA Label Image

Figure 4 (Desvenlafaxine Image4)

A Kaplan-Meier survival curve showing the estimated proportion of patients with relapse (%) over time up to 200 days from randomization. The graph compares Desvenlafaxine Extended-Release Tablets 50 mg (solid line) with placebo (dashed line), illustrating lower relapse rates over time for the Desvenlafaxine group than placebo.*

FDA Label Image

Figure 5 (Desvenlafaxine Image5)

A Kaplan-Meier survival curve showing the estimated proportion of patients with relapse (%) over time in days from randomization. The chart compares Desvenlafaxine Extended-Release Tablets and Placebo groups, with relapse proportions increasing over time for both groups, Placebo showing a higher relapse rate.*

FDA Label Image

Structure (Desvenlafaxine Structure1)

Chemical structure diagram of Desvenlafaxine Succinate monohydrate, showing molecular groups including hydroxyl, carboxyl, methyl, and nitrogen atoms in the formula.*

FDA Label Image

Label (Lbl713352130)

Desvenlafaxine ER 25 mg extended-release tablet packaging label from Bryant Ranch Prepack. The label includes a comparison reference to Pristiq 25 mg tablets by Alembic Pharmaceuticals Limited. It describes the tablet as brown (tan), round, and biconvex. The label states storage instructions at room temperature (20°-25°C) and includes warnings to keep drugs out of reach of children. The package count is 30 tablets and features the NDC 71335-2130-1.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.